Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinomaKazuya Ofuji, Tetsuya Nakatsura, Hirofumi Shirakawa et al.|Oncotarget|2016Cited by 28
Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptideYoshitaka Tada, Tetsuya Nakatsura, Toshiaki Yoshikawa et al.|International Journal of Oncology|2013Cited by 25